Francisco Leon, Tolerance Bio CEO
October 15, 2024 07:00 AM EDTUpdated 07:12 AM
Financing
Startups

Tol­er­ance Bio emerges from stealth with $17.2M to ad­vance ther­a­pies de­vel­oped from the thy­mus

Katherine Lewin

News Reporter

Tol­er­ance Bio has launched with an over­sub­scribed $17.2 mil­lion seed round and a goal to de­vel­op ther­a­pies for im­mune-me­di­at­ed dis­eases, from can­cer to trans­plant re­jec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times